Original Article | Published:

CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior

Molecular Psychiatry volume 23, pages 872882 (2018) | Download Citation

Abstract

The serotonergic neurotransmitter system has been widely implicated in the pathophysiology of mood-related disorders such as anxiety and major depressive disorder (MDD). The onset of therapeutic efficacy of traditional antidepressants is delayed by several weeks. The 5-HT4 receptor has emerged as a new therapeutic target since agonists of this receptor induce rapid antidepressant-like responses in rodents. Here we show that the 5-HT4 receptor is regulated by CK2, at transcriptional and post-transcriptional levels. We present evidence, in two different CK2α knockout mouse lines, that this regulation is region-specific, with the 5-HT4 receptor upregulated in prefrontal cortex (PFC) but not striatum or hippocampus where CK2α is also ablated. 5-HT4 receptor signaling is enhanced in vitro, as evidenced by enhanced cAMP production or receptor plasma membrane localization in the presence of CK2 inhibitor or shRNA targeting CK2α. In vivo, 5-HT4 receptor signaling is also upregulated since ERK activation is elevated and sensitive to the inverse agonist, GR113808 in the PFC of CK2α KO mice. Behaviorally, KO mice as well as mice with AAV-mediated deletion of CK2α in the PFC show a robust ‘anti-depressed-like’ phenotype and display an enhanced response to antidepressant treatment when tested in paradigms for mood and anxiety. Importantly, it is sufficient to overexpress the 5-HT4 receptor in the mPFC to generate mice with a similar ‘anti-depressed-like’ phenotype. Our findings identify the mPFC as the region that mediates the effect of enhanced 5-HT4 receptor activity and CK2 as modulator of 5-HT4 receptor levels in this brain region that regulates mood-related phenotypes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.

  2. 2.

    , , , , . The role of transcranial magnetic stimulation in treatment-resistant depression: a review. Curr Pharm Des 2012; 18: 5846–5852.

  3. 3.

    , , , , , et al. Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 2014; 39: 1366–1378.

  4. 4.

    , , , , , et al. Serotonin 1A and Serotonin 4 receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 2016; 22: 26–45.

  5. 5.

    , , , , , et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631–643.

  6. 6.

    , , , , , et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55: 712–725.

  7. 7.

    , , , , , . Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38: 317–327.

  8. 8.

    , , , , , et al.Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int 2011; 59: 896–905.

  9. 9.

    , , , . Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1205–1210.

  10. 10.

    , , , , , . Identification of the cortical neurons that mediate antidepressant responses. Cell 2012; 149: 1152–1163.

  11. 11.

    , , , , , et al. Familial risk for major depression is associated with lower striatal 5-HT(4) receptor binding. Int J Neuropsychopharmacol 2014; 18: 1–7.

  12. 12.

    , , , , , et al. Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH Genetics Initiative Bipolar Pedigrees. Mol Psychiatry 2002; 7: 954–961.

  13. 13.

    , , , , , et al. Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors 2010; 36: 187–195.

  14. 14.

    , . Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci 2009; 66: 1830–1839.

  15. 15.

    , , , . Regulation of protein kinase CK2 isoform expression during rat brain development. Cell Mol Biol Res 1994; 40: 581–585.

  16. 16.

    , , , , , . Structure of the human protein kinase CK2 catalytic subunit CK2alpha' and interaction thermodynamics with the regulatory subunit CK2beta. J Mol Biol 2011; 407: 1–12.

  17. 17.

    , , , . Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J Neurosci 2004; 24: 10248–10259.

  18. 18.

    , , , . Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron 67: 984–996.

  19. 19.

    , , , , , et al. Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem 2004; 279: 6834–6839.

  20. 20.

    , , , , , et al. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc Natl Acad Sci USA 2001; 98: 3080–3085.

  21. 21.

    , , , , , . An AUTS2-polycomb complex activates gene expression in the CNS. Nature 2014; 516: 349–354.

  22. 22.

    , , , , . Selective knockout of the casein kinase 2 in d1 medium spiny neurons controls dopaminergic function. Biol Psychiatry 2013; 74: 113–121.

  23. 23.

    , , , , , . Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. Fundam Clin Pharmacol 2009; 23: 23–42.

  24. 24.

    , , . Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 2006; 78: 1933–1939.

  25. 25.

    , , , , , . Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci 2002; 22: 6309–6314.

  26. 26.

    , , , , , . Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci USA 1992; 89: 3020–3024.

  27. 27.

    , . The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 2009; 10: 1118–1138.

  28. 28.

    , . 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 1–10.

  29. 29.

    , , , , , et al. Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce expression of fear and depression-like behavior. Biol Psychiatry 2011; 69: 780–787.

  30. 30.

    , , , , , et al. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 2000; 36: 35–46.

  31. 31.

    , , , . 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 39–51.

  32. 32.

    , . Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699–771.

  33. 33.

    . Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 2009; 119: 717–725.

  34. 34.

    , , , , , et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085–1098.

  35. 35.

    , , , , , et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311: 77–80.

  36. 36.

    , , , . Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology 2011; 61: 442–450.

  37. 37.

    , , , , , et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008; 135: 738–748.

  38. 38.

    , . Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65: 7–19.

  39. 39.

    , , . Four exons of the serotonin receptor 4 gene are associated with multiple distant branch points. RNA 2010; 16: 839–851.

  40. 40.

    , , , , , . CK2 negatively regulates Galphas signaling. Proc Natl Acad Sci USA 2009; 106: 14096–14101.

  41. 41.

    , , , . activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J Biol Chem 2003; 278: 3098–3104.

  42. 42.

    , , , , , et al. 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 2007; 18: 1979–1991.

  43. 43.

    , , , , . Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 2004; 19: 1826–1836.

  44. 44.

    , . Cell-specific extracellular signal-regulated kinase activation by multiple G protein-coupled receptor families in hippocampus. Mol Pharmacol 2003; 63: 128–135.

  45. 45.

    , , . The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571–625.

  46. 46.

    , . Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771–783.

  47. 47.

    , , , , . The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988; 95: 298–302.

  48. 48.

    , . Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007; 10: 1116–1124.

  49. 49.

    , , , , , et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651–660.

  50. 50.

    , , , , , et al. Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of DeltaFosB. J Neurosci 2014; 34: 3878–3887.

  51. 51.

    , , , , , et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature 2012; 492: 428–432.

  52. 52.

    , , , , , et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 2005; 57: 918–925.

  53. 53.

    , , , , , et al. Serotonin 5-HT4 receptors: a new strategy for developing fast acting antidepressants? Curr Pharm Des 2014; 20: 3751–3762.

  54. 54.

    , , , , , . Connection re-established: neurotransmission between the medial prefrontal cortex and serotonergic neurons offers perspectives for fast antidepressant action. Neuropsychiatry 2011; 1: 165–177.

  55. 55.

    , , , , , et al. Functional studies of the 5'-untranslated region of human 5-HT4 receptor mRNA. Biochem J 2005; 387(Pt 2): 463–471.

  56. 56.

    , , , , , et al. Serotonin 1A and Serotonin 4 receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 2016; 22: 26–45.

  57. 57.

    , , , , , et al. Casein kinase II as a potentially important enzyme concerned with signal transduction. Cold Spring Harb Symp Quant Biol 1988; 53(Pt 1): 77–84.

  58. 58.

    , , , . Cyclic-AMP-responsive transcriptional activation of CREB-327 involves interdependent phosphorylated subdomains. Embo J 1990; 9: 4455–4465.

  59. 59.

    , , , , , et al. Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol Cell Biol 2010; 30: 2737–2749.

  60. 60.

    , , , , , . 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 1998; 861: 49–56.

  61. 61.

    , , , . Protein kinase CK2 is required for Wntless internalization and Wnt secretion. Cell Signal 2014; 26: 2601–2605.

  62. 62.

    , , , . Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 2016; 21: 313–319.

  63. 63.

    , , , , . Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35–41.

  64. 64.

    , , , , , . GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013; 38: 2268–2277.

  65. 65.

    , , . Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 2005; 183: 257–264.

  66. 66.

    , , . Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001; 155: 315–322.

  67. 67.

    , , , , , et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 2013; 3: e253.

  68. 68.

    , , , , , et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 2014; 28: 179–182.

  69. 69.

    , , , . The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol 2015; 6: 70.

Download references

Acknowledgements

We thank Drs S Claeyssen and J Bockaert (INSERM-Montpellier) for the HA-HTR4 plasmid and Drs K Salas-Ramirez and A Kottmann (CCNY) for use of equipment. This work was supported by PSC-CUNY44, 45, 46 and 47 to HR and PSC-CUNY45 to BLF.

Author information

Affiliations

  1. Department of Physiology, Pharmacology and Neuroscience, CUNY School of Medicine, New York, NY, USA

    • J Castello
    • , B LeFrancois
    • , E Friedman
    •  & H Rebholz
  2. Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, USA

    • M Flajolet
    •  & P Greengard
  3. Programs in Biochemistry and Biology, The Graduate Center, City University of New York, New York, NY, USA

    • E Friedman

Authors

  1. Search for J Castello in:

  2. Search for B LeFrancois in:

  3. Search for M Flajolet in:

  4. Search for P Greengard in:

  5. Search for E Friedman in:

  6. Search for H Rebholz in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to H Rebholz.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/mp.2017.240

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)